Plasmepsin2-3 Copy Number Detection for Piperaquine Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The spread of artemisinin-resistant Plasmodium falciparum malaria, particularly in western Cambodia, has led to high treatment failure rates with dihydroartemisinin-piperaquine (DHA-PPQ), necessitating a reliable method to detect piperaquine resistance, as existing methods are logistically demanding and inefficient.
Innovation Solution
The development of an in-vitro Piperaquine Survival Assay (PSA) and genotyping methods to detect increased copy numbers of the plasmepsin2-3 cluster, specifically using quantitative PCR (qPCR) to identify molecular markers associated with piperaquine resistance, allowing for the prediction of treatment failure and resistance risk.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If logistically demanding 42-day follow up studies are used to detect piperaquine resistance, then detection reliability is improved, but operational complexity and time consumption increase
Solution Approach 1:
The patent extracts the essential detection function from complex longitudinal studies by identifying and measuring specific molecular markers (pfpm2 copy number) that directly indicate piperaquine resistance. This extraction allows detection without requiring 42-day follow-up, reducing operational complexity while maintaining reliability.
Solution Approach 2:
The patent replaces the mechanical/observational system of 42-day clinical follow-up with a molecular biology-based detection system using qPCR to measure pfpm2 copy number. This substitution eliminates the need for prolonged patient monitoring while providing reliable resistance detection.
2Loss of time
If molecular markers are used to predict treatment failure, then time efficiency is improved, but measurement precision requirements increase
Solution Approach 1:
The patent changes the detection parameter from clinical outcomes measured over 42 days to molecular marker quantification (pfpm2 copy number) that can be measured immediately. This parameter change enables rapid prediction of treatment failure while requiring precise molecular measurement techniques like qPCR.
3Speed
If in-vitro PSA is used to identify resistance, then detection speed is improved, but resource requirements increase
Solution Approach 1:
The patent performs preliminary molecular characterization (pfpm2 copy number measurement) on parasite isolates before clinical treatment. This preliminary action identifies resistant strains in advance, enabling rapid detection without requiring resource-intensive in-vitro drug exposure assays while still providing speed benefits.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides a reliable and efficient means to predict DHA-PPQ treatment failures by identifying amplification of the PƒPM2 locus, correlating with piperaquine resistance and aiding in antimalarial treatment policies and containment measures.
Implementation Method 1
detecting the presence of an increased copy number of the genomic plasmepsin2-3 cluster... In a preferred embodiment the PCR is quantitative PCR (qPCR)
Data Source
AI summary
A method for genotyping a plasmodium comprising: (a) providing a sample containing a Plasmodium; and (b) detecting the presence of an increased copy number of the genomic plasmepsin2-3 cluster. A method for the detection of a plasmodium infection in a patient comprising: (a) providing a blood sample from a patient and (b) detecting the presence or absence of an increased copy number of the genomic plasmepsin2-3 cluster in the blood sample. Kits for genotyping a plasmodium and/or detection of a plasmodium infection. Methods of treating a plasmodium infection.